This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Deciphera Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Deciphera Pharmaceuticals hat ein Gesamteigenkapital von $316.1M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $420.9M bzw. $104.9M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$272.53m
Eigenkapital	US$316.05m
Gesamtverbindlichkeiten	US$104.88m
Gesamtvermögen	US$420.93m

Jüngste Berichte zur Finanzlage

Analyseartikel • Mar 13

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Dec 02

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyseartikel • Jul 26

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Apr 10

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Dec 29

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Recent updates

Analyseartikel • Apr 30

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Deciphera Pharmaceuticals, Inc. ( NASDAQ:DCPH ) shares have continued their recent momentum with a 61% gain in the last...

Seeking Alpha • Apr 26

Diving Into Deciphera Pharmaceuticals

Summary Shares of Deciphera Pharmaceuticals, Inc. have rallied 40% since October after positive trial data for vimseltinib in the treatment of TGCT. Vimseltinib is expected to make significant progress in the TGCT indication, as the only approved therapy is under a Risk Evaluation and Mitigation Strategy protocol. Deciphera's switch-control kinase inhibitor platform aims to produce compounds that target specific regions of kinases, resulting in higher activity and lower toxicity compared to current kinase inhibitors. An investment analysis around Deciphera Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha

Analyseartikel • Mar 13

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Dec 02

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyseartikel • Sep 25

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Key Insights Deciphera Pharmaceuticals' estimated fair value is US$21.93 based on 2 Stage Free Cash Flow to Equity...

Analyseartikel • Jul 26

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Jun 22

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Key Insights Deciphera Pharmaceuticals' estimated fair value is US$16.23 based on 2 Stage Free Cash Flow to Equity...

Analyseartikel • May 08

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

Deciphera Pharmaceuticals, Inc.'s ( NASDAQ:DCPH ) price-to-sales (or "P/S") ratio of 7.7x might make it look like a buy...

Analyseartikel • Apr 10

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Dec 29

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Seeking Alpha • Aug 29

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Deciphera Pharmaceuticals (NASDAQ:DCPH) has been initiated as a buy at Cowen based on growth in sales of its advanced gastrointestinal stromal tumor treatment Qinlock (ripretinib) and its pipeline. The firm has a $25 price target (~68% upside based on Friday's close). Analyst Tyler Van Buren said that Decipera (DCPH) pipeline is "poised to break out" and a significant catalyst could come next month at the European Society for Medical Oncology (ESMO) annual meeting with data on vimseltinib and DCC-3116. Vimseltinib is in phase 1/2 for tenosynovial giant cell tumor, while DCC-3116 is in phase 1 for RAS/RAF mutant cancers in combination with Mekinist (trametinib). He added he sees peak sales of both candidates at a combined ~$1.3B. Seeking Alpha's Quant Rating view Deciphera as a buy with high marks for momentum, growth, and revisions.

Seeking Alpha • Aug 03

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Deciphera Pharmaceuticals (NASDAQ:DCPH) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.67 (vs. -$1.21 last year) and the consensus Revenue Estimate is $30.11M (+27.7% Y/Y). Over the last 3 months, EPS estimates have seen 4 upward revisions and 3 downward. Revenue estimates have seen 5 upward revisions and 3 downward.

Analyseartikel • Jul 29

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Feb 11

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Deciphera's ripretinib failed a critical trial. The stock has been decimated. Although the company is struggling to make a comeback, it will take time.

Seeking Alpha • Nov 22

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Deciphera Pharmaceuticals is the unusual case of a commercial-stage company whose drug succeeds at first but then has a major setback. Top-line data from a key phase 3 trial suggest that their flagship drug will not be moving from later-line to second-line therapy for GIST. With buoying expenses, Deciphera needs to make a splash to increase revenues quickly, or else dilution is a serious risk. Though risky overall, Deciphera at these levels presents a very interesting risk/benefit case.

Analyseartikel • Aug 26

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • May 10

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: DCPHDie kurzfristigen Aktiva des Unternehmens ($349.9M) übersteigen seine kurzfristigen Passiva ($83.4M).

Langfristige Verbindlichkeiten: DCPHDie kurzfristigen Vermögenswerte des Unternehmens ($349.9M) übersteigen seine langfristigen Verbindlichkeiten ($21.4M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: DCPH ist schuldenfrei.

Schulden abbauen: DCPH hat keine Schulden im Vergleich zu vor 5 Jahren, als das Verhältnis von Schulden zu Eigenkapital 0.5% betrug.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: DCPH auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: DCPH verfügt über eine ausreichende Liquiditätsreserve für 1.7 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 9.2% pro Jahr abnimmt.

Entdecken Sie finanziell stabile Unternehmen

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2024/06/11 00:24
Aktienkurs zum Tagesende	2024/06/11 00:00
Gewinne	2024/03/31
Jährliche Einnahmen	2023/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Deciphera Pharmaceuticals, Inc. wird von 15 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Madhu Kumar	B. Riley Securities, Inc.
Arlinda Lee	Canaccord Genuity
Charles Duncan	Cantor Fitzgerald & Co.

This company has been acquired

Deciphera Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Deciphera Pharmaceuticals, Inc. Files Form 15

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Recent updates

Deciphera Pharmaceuticals, Inc. Files Form 15

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index

Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (Tgct) At the 2024 Asco Annual Meeting and Online Publication in the Lancet

First quarter 2024 earnings released: US$0.52 loss per share (vs US$0.60 loss in 1Q 2023)

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Price target increased by 7.1% to US$25.38

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Diving Into Deciphera Pharmaceuticals

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus estimates of losses per share improve by 12%

Deciphera Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18

President recently sold US$471k worth of stock

Senior VP & Chief Commercial Officer recently sold US$224k worth of stock

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

President recently sold US$259k worth of stock

Price target increased by 11% to US$24.44

Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023

Deciphera Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc. to Present Data from INTRIGUE Phase 3 Study of QINLOCK (ripretinib) and Trial-In-Progress Poster for Insights Pivotal Phase 3 Study of QINlock (Rpretinib) at the 2023 American Society of Clinical Oncology Annual Meeting

Independent Director recently bought US$152k worth of stock

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

First quarter 2023 earnings: EPS and revenues miss analyst expectations

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

President notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Executive VP recently sold US$51k worth of stock

Now 20% undervalued

Price target increased to US$21.10

Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Price target increased to US$20.25

Deciphera Pharmaceuticals, Inc. Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Insufficient new directors

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Price target decreased to US$59.27

Third quarter 2021 earnings released: US$1.37 loss per share (vs US$1.13 loss in 3Q 2020)

Executive VP & Chief Medical Officer recently sold US$88k worth of stock

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Second quarter 2021 earnings released: US$1.22 loss per share (vs US$1.20 loss in 2Q 2020)

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

Director notifies of intention to sell stock

First quarter 2021 earnings released: US$1.06 loss per share (vs US$1.36 loss in 1Q 2020)

Independent Chairman exercised options and sold US$586k worth of stock

Director exercised options and sold US$349k worth of stock

President notifies of intention to sell stock

New 90-day low: US$40.39

Analyse der Finanzlage